Hori R, Okumura K, Yasuhara M, Katayama H
Biochem Pharmacol. 1985 Aug 1;34(15):2679-83. doi: 10.1016/0006-2952(85)90567-2.
The effect of acute renal failure (ARF) on the hepatic uptake and metabolism of propranolol was investigated in relation to the hepatic clearance of the drug. ARF was induced by the subcutaneous injection of uranyl nitrate to rats. The uptake rate of propranolol in the isolated perfused liver was determined by the multiple-indicator dilution method and was found to decrease from 43.6 +/- 2.0 min-1 (mean +/- S.E.) in control to 29.4 +/- 1.7 min-1 in ARF (P less than 0.001). The recovery fraction of propranolol in effluent venous blood increased about twofold in ARF compared to control (P less than 0.05). The metabolic activity for propranolol was examined using the hepatic microsomal fraction prepared from control and ARF rats. There was no significant difference in the kinetics of oxidative metabolism of propranolol between two groups. These results suggest that the previously reported decrease in the hepatic clearance of propranolol in ARF is due to decreased hepatic uptake of the drug from the blood into the liver cells.
研究了急性肾衰竭(ARF)对普萘洛尔肝脏摄取和代谢的影响,并与该药物的肝脏清除率相关联。通过向大鼠皮下注射硝酸铀酰诱导ARF。采用多指示剂稀释法测定离体灌注肝脏中普萘洛尔的摄取率,发现其从对照组的43.6±2.0 min⁻¹(平均值±标准误)降至ARF组的29.4±1.7 min⁻¹(P<0.001)。与对照组相比,ARF组流出静脉血中普萘洛尔的回收分数增加了约两倍(P<0.05)。使用从对照组和ARF组大鼠制备的肝微粒体部分检测普萘洛尔的代谢活性。两组之间普萘洛尔氧化代谢的动力学没有显著差异。这些结果表明,先前报道的ARF中普萘洛尔肝脏清除率的降低是由于药物从血液进入肝细胞的肝脏摄取减少所致。